Immunogen (IMGN) Posts Q4 Loss of 71c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2015 Financial Results
July 31, 2015 6:30 AM EDTCompany Provides Corporate Update and Fiscal Year 2016 Financial Guidance
Conference Call Today at 8:00 am ET
ImmunoGens wholly owned mirvetuximab soravtansine demonstrates notable single-agent activity in early clinical testing for platinum-resistant ovarian cancer; Company plans to initiate later-stage testing this year. Events expected with other ImmunoGen product candidates in 2H2015 include initiation of clinical assessment of IMGN529 in combination with rituximab (Rituxan®) and submission of the IMGN779 IND. Events expected among partner compounds in the next 12 months include presentation of new clinical data, start of... More